Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351729 | 0.80 | TSHR (0.56) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL8839139 | 0.74 | MAPK1 (0.55) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL4838438 | 0.72 | TSHR (0.48) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL3203801 | 0.72 | TSHR (0.48) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL17471306 | 0.72 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL8958906 | 0.71 | LPAR1 (0.41) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL25869402 | 0.71 | LMNA (0.58) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL12555905 | 0.70 | MAPK1 (0.46) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL17278043 | 0.70 | USP2 (0.55) | TSHRHTTMEN1THRBKMT2A | |
| SCHEMBL21392856 | 0.70 | ALDH1A1 (0.52) | TSHRHTTMEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753638-B2 | Conjugated oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753638-B2 | Conjugated oligonucleotides | DCLRE1B, DCLRE1A, TNNC1 | TSHR 1065/4885HTT 3439/4885MEN1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.